

# PROBI AB

## INTERIM REPORT JANUARY - SEPTEMBER

### Down payment through Danone deal affects turnover and result positively in third quarter

- **Net sales** for the reporting period amounted to 58.5 million SEK (49.7) and 26.7 million SEK (14.3) for the third quarter.
- **EBIT** for the reporting period amounted to 15.1 million SEK (12.0) and 9.2 million SEK (3.1) for the third quarter.
- **Profit after tax** for the reporting period amounted to 11.3 million SEK (9.3) and 6.7 million SEK (2.1) for the third quarter.
- **After tax earnings per share** for the reporting period amounted to 1.20 SEK (1.00) and 0.72 SEK (0.23) for the third quarter.
- **Cash flow** for the reporting period amounted to 5.7 million SEK (11.6) and 0.8 million SEK (2.5) for the third quarter.
- Probi signed a ten year license agreement with Danone and reports a lump sum revenue of approximately 10 million SEK in the third quarter. The amount will be paid by Skånemejerier in the fourth quarter.
- Write-down of capitalized expenditure for development by 3.0 million SEK.
- Probi has established a leading position on the Swedish probiotic supplements market through the cooperation with Bringwell.
- Expansion of Probi's cooperation with Camox Pharmaceuticals in South Africa.

#### CEO's-COMMENTS:

"The agreements we signed with Danone regarding ProViva is of great long term value to Probi. The agreements ensure revenues on the Swedish market and we see great potential in the possibility of international launch. We are also pleased to note that we have organic growth of 17 per cent for the quarter; which, amongst other things, is due to the successful launch of ProbiMage and ProbiFrisk," says Michael Oredson, CEO of Probi.

#### FOR FURTHER INFORMATION, CONTACT:

Michael Oredsson, CEO Probi, phone: +46 46 286 89 23 or +46 707 18 89 30; e-mail: michael.oredsson@probi.se

Distributed 2010-10-20, 09.10 (CET)

#### ABOUT PROBI

Probi is a leading player in probiotics research and the development of efficient and well-documented probiotics. The research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi's customers are leading companies in the functional foods and dietary supplement business areas. Total income for 2009 was MSEK 66.2, of which the majority represented royalties. Probi's share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500 shareholders. For more information, please visit [www.probi.se](http://www.probi.se).